A registry trial of SGLT-2 inhibition in low-risk patients after an MI showed some benefit in preventing future events, but a larger study would be warranted to further validate the signal.
For adults with early-stage chronic kidney disease (CKD), a proprietary formula performed well in stratifying risk of progression to more severe kidney dysfunction and of increased healthcare needs.
A new analysis of a large contemporary registry of patients with cardiogenic shock has shown worse outcomes for women than men, driven particularly by those with shock related to heart failure.